Cancer Cell Therapy Market Sales Revenue Clinical Trials Pipeline Report

Since the past 3-5 years, a more complex therapeutic modality has been is emerging as cell therapies which have been developed to treat diseases which are not amenable to treatment with more classical pharmaceutical or biopharmaceutical products. This market offers the promise of successfully regenerating damaged tissues and organs in the body by replacing the damaged tissue and/or by stimulating the body’s own repair mechanisms to heal previously irreparable tissues. With their rising popularity, these therapies are becoming more cost effective and efficient.

Download Report:

https://www.kuickresearch.com/report-Cancer-Cell-Therapy-Market-&-Pipeline-Insight.php

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

Cancer Cell Therapy Market & Pipeline Insight" Table of Contents

1. Introduction to Cell Therapy
1.1 Origin of Cell Therapy
1.2 Composition of Cell Therapy

2. Introduction to Cancer Therapies
2.1 Types of Stem Cell Transplants for Treating Cancer
2.2 Dendritic Cell Therapy
2.3 Targeted Cancer Therapies

3. Cancer Cell Therapy Market Overview
3.1 Market Overview
3.2 Clinical Pipeline Insight

4. Global Cancer Cell Therapy Market Dynamics
4.1 Market Drivers
4.2 Market Challenges
4.3 Future Outlook

5. Cancer Cell Therapy Drug Clinical Trial Insight by Phase, Country & Target Indications
5.1 Unknown Phase
5.2 Research
5.3 Preclinical
5.4 Clinical
5.5 Phase I
5.6 Phase I/II
5.7 Phase II
5.8 Phase III

6. Marketed Cancer Cell Therapy Clinical Insight & Patent Analysis

7. Suspended & Discontinued Cancer Cell Therapy Clinical Insight
7.1 No Development Reported
7.2 Discontinued
7.3 Suspended

8. Competitive Landscape
8.1 Adaptimmune
8.2 Apceth
8.3 Argos Therapeutics Inc
8.4 Celgene Cellular Therapeutics
8.5 Cellerant Therapeutics
8.6 Immunicum
8.7 Innate Pharma
8.8 Innocell Corporation
8.9 Kite Pharma
8.10 Takara Bio

Figure 1-1: Four Pillars of Global Pharmaceutical Industry
Figure 1-2: Composition of Cell Therapy
Figure 2-1: Cancer Therapies Overview
Figure 3-1: Global Cell Therapy Market (US$ Billion), 2012-2018
Figure 3-2: Global Cell Therapy Market by Indications, 2013
Figure 3-3: Global Cell Therapy Market by Region (%), 2013 & 2018
Figure 3-4: Global Cancer Cell Therapy Market (US$ Billion), 2012-2018
Figure 3-5: Cancer Cell Therapy Clinical Pipeline by Phase (%), 2014
Figure 3-6: Cancer Cell Therapy Clinical Pipeline by Phase (Number), 2014
Figure 3-7: No Development Reported in Cancer Cell Therapy Clinical Pipeline by Phase (%), 2014
Figure 3-8: No Development Reported in Cancer Cell Therapy Clinical Pipeline by Phase (Number), 2014
Figure 3-9: Discontinued Cancer Cell Therapy Clinical Pipeline by Phase (%), 2014
Figure 3-10: Discontinued Cancer Cell Therapy Clinical Pipeline by Phase (Number), 2014
Figure 8-1: Adaptimmune Clinical Pipeline Insight
Figure 8-2: Apceth Clinical Pipeline Insight
Figure 8-3: Argos Therapeutics Clinical Pipeline Insight
Figure 8-4: Cellerant Clinical Pipeline Insight
Figure 8-5: Immunicum Clinical Pipeline Insight
Figure 8-6: Innate Pharma Clinical Pipeline Insight
Figure 8-7: Kite Pharma Clinical Pipeline Insight

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.